摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(甲基氨基)-3-(1-哌嗪基)-2-丙醇 | 134699-02-8

中文名称
1-(甲基氨基)-3-(1-哌嗪基)-2-丙醇
中文别名
——
英文名称
1-(5-hydroxy-3-azapentyl)piperazine
英文别名
2-((2-(Piperazin-1-yl)ethyl)amino)ethanol;2-(2-piperazin-1-ylethylamino)ethanol
1-(甲基氨基)-3-(1-哌嗪基)-2-丙醇化学式
CAS
134699-02-8
化学式
C8H19N3O
mdl
——
分子量
173.258
InChiKey
KOCRVTCEUXRPPI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.5
  • 重原子数:
    12
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    47.5
  • 氢给体数:
    3
  • 氢受体数:
    4

SDS

SDS:ae3962faed9ddba709aa13b301e66c73
查看

反应信息

  • 作为反应物:
    描述:
    1-(甲基氨基)-3-(1-哌嗪基)-2-丙醇盐酸 作用下, 生成 1-Piperazineethanamine, N-(2-chloroethyl)-, trihydrochloride
    参考文献:
    名称:
    Bobylev, V. A.; Chechik, V. O., Journal of general chemistry of the USSR, 1990, vol. 60, # 12.1, p. 2438 - 2442
    摘要:
    DOI:
  • 作为产物:
    描述:
    1-羟乙基氮丙啶哌嗪盐酸 作用下, 以 为溶剂, 反应 3.0h, 以60%的产率得到1-(甲基氨基)-3-(1-哌嗪基)-2-丙醇
    参考文献:
    名称:
    Bobylev, V. A.; Chechik, V. O., Journal of general chemistry of the USSR, 1990, vol. 60, # 12.1, p. 2438 - 2442
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR<br/>[FR] INHIBITEURS DE TRIAZOLE BIARYLE DU FACTEUR INHIBITEUR DE LA MIGRATION DES MACROPHAGES
    申请人:UNIV YALE
    公开号:WO2016130968A1
    公开(公告)日:2016-08-18
    The present disclosure describes biaryl triazole compounds, as well as their compositions and methods of use. The compounds inhibit the activity of macrophage migration inhibitory factor and are useful for the treatment of diseases, e.g., inflammatory diseases and cancer.
    本公开描述了联苯三唑化合物,以及它们的组合物和使用方法。这些化合物抑制巨噬细胞迁移抑制因子的活性,并且对于治疗疾病,例如炎症性疾病和癌症,具有用处。
  • [EN] PROCESS FOR MANUFACTURING CHAIN-EXTENDED HYDROXYETHYLETHYLENEAMINES, ETHYLENEAMINES, OR MIXTURES THEREOF<br/>[FR] PROCÉDÉ DE FABRICATION D'HYDROXYÉTHYLÉTHYLÈNEAMINES À CHAÎNE ÉTENDUE, D'ÉTHYLÈNEAMINES OU DE MÉLANGES DE CELLES-CI
    申请人:AKZO NOBEL CHEMICALS INT BV
    公开号:WO2018166938A1
    公开(公告)日:2018-09-20
    The invention pertains to a process for preparing hydroxyethylethyleneamines, ethyleneamines, or mixtures thereof, and/or ethylene urea derivatives thereof comprising the step of reacting diethanolamine with an amine-functional compound comprising at least two –NH-units of which at least one is selected from the group of primary amine groups and cyclic secondary amine groups, the amine-functional compound comprising at least one –NH-CH2-CH2-NH-unit wherein one or more -NH- CH2-CH2-NH-units in the amine-functional compound may be present in the form of cyclic ethylene urea moieties, piperazine moieties, or linear ethylene urea moieties, in the presence of a carbon oxide delivering agent, wherein -the molar ratio of amine-functional compound to diethanolamine is at least 0.2:1, and -the molar ratio of carbon oxide delivering agent to –NH-CH2-CH2-NH-units in the amine-functional compound is at least 0.1:1. The invention makes it possible to obtain higher hydroxyethylethyleneamines, ethyleneamines, or mixtures thereof, and/or ethylene urea derivatives thereof from diethanolamine, which is an attractive starting material.
    该发明涉及一种制备羟乙基乙烯胺、乙烯胺或二者的混合物,和/或其乙烯脲衍生物的过程,包括将二乙醇胺与一种含有至少两个-NH-基团的胺基化合物反应的步骤,其中至少一个选自一次胺基团和环状二次胺基团的组中,该胺基化合物包括至少一个-NH-CH2-CH2-NH-基团,其中该胺基化合物中的一个或多个-NH-CH2-CH2-NH-基团可以以环状乙烯脲基团、哌嗪基团或线性乙烯脲基团的形式存在,存在一种碳氧化物传递剂的情况下,其中-胺基化合物与二乙醇胺的摩尔比至少为0.2:1,和-碳氧化物传递剂与胺基化合物中的-NH-CH2-CH2-NH-基团的摩尔比至少为0.1:1。该发明使得从二乙醇胺中获得更高的羟乙基乙烯胺、乙烯胺或二者的混合物,和/或其乙烯脲衍生物成为可能,而二乙醇胺是一种有吸引力的起始原料。
  • Quinazoline derivatives and their use in the treatment of cancer
    申请人:Hennequin Francois Andre Laurent
    公开号:US20060211714A1
    公开(公告)日:2006-09-21
    The invention concerns quinazoline derivatives of the formula: (I); wherein X 1 , Q 1 , Z, R 1 , R 2 , Y, a and m are as defined in the description, which are erbB tyrosine kinase inhibitors, particularly EGFR tyrosine kinase inhibitors. Also claimed are processes for their preparation; pharmaceutical compositions containing them; and their use as therapeutic agents in the treatment of erbB tyrosine kinase mediated diseases such as cancer.
    本发明涉及公式(I)的喹唑啉衍生物;其中X1,Q1,Z,R1,R2,Y,a和m如描述中所定义,它们是erbB酪氨酸激酶抑制剂,特别是EGFR酪氨酸激酶抑制剂。还声明了它们的制备方法;包含它们的药物组合物;以及它们作为治疗erbB酪氨酸激酶介导的疾病,如癌症的治疗剂的用途。
  • Process to prepare higher ethylene amines and ethylene amine derivatives
    申请人:Akzo Nobel Chemicals International B.V.
    公开号:US10995077B2
    公开(公告)日:2021-05-04
    The present invention relates to a process to prepare ethyleneamines of the formula NH2—(C2H4—NH—)pH wherein p is at least 2 wherein one or more units —NH—C2H4—NH— are present as a piperazine unit or precursors thereof wherein optionally one or more units —NH—C2H4—NH— are present as a cyclic ethylene urea unit or between two units —NH—C2H4—NH— a carbonyl moiety is present, by reacting an ethanolamine-functional compound, an amine-functional compound in the presence of a carbon oxide delivering agent, wherein at least one of the amine-functional compound or the ethanolamine-functional compound contains a piperazine unit, and the reaction is performed in a liquid that comprises water.
    本发明涉及一种制备式 NH2-(C2H4-NH-)pH(其中 p 至少为 2)的乙烯胺的工艺,其中一个或多个单元 -NH-C2H4-NH- 作为哌嗪单元或其前体存在,其中任选一个或多个单元 -NH-C2H4-NH- 作为环状乙烯脲单元存在或在两个单元 -NH-C2H4-NH- 之间存在一个羰基、使乙醇胺官能团化合物和胺官能团化合物在氧化碳传递剂存在下反应,其中胺官能团化合物或乙醇胺官能团化合物中至少有一个含有哌嗪单元,反应在含水的液体中进行。
  • BOBYLEV, V. A.;CHECHIK, V. O., ZH. OBSHCH. XIMII, 60,(1990) N2, S. 2721-2725
    作者:BOBYLEV, V. A.、CHECHIK, V. O.
    DOI:——
    日期:——
查看更多